Trade Inovio Pharmaceuticals, Inc. - INO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0522 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.8889 |
| Open | 1.8939 |
| 1-Year Change | 158.55% |
| Day's Range | 1.8939 - 2.0789 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 2.0639 | 0.1500 | 7.84% | 1.9139 | 2.0789 | 1.8789 |
| Jan 16, 2025 | 1.8889 | 0.0350 | 1.89% | 1.8539 | 1.8889 | 1.8039 |
| Jan 15, 2025 | 1.8389 | -0.0250 | -1.34% | 1.8639 | 1.9039 | 1.8189 |
| Jan 14, 2025 | 1.8489 | -0.0350 | -1.86% | 1.8839 | 1.9289 | 1.7989 |
| Jan 13, 2025 | 1.8789 | -0.0300 | -1.57% | 1.9089 | 1.9089 | 1.7839 |
| Jan 10, 2025 | 1.9489 | -0.0550 | -2.74% | 2.0039 | 2.0289 | 1.9239 |
| Jan 8, 2025 | 2.0589 | -0.2350 | -10.24% | 2.2939 | 2.2939 | 1.9889 |
| Jan 7, 2025 | 2.2689 | 0.3500 | 18.24% | 1.9189 | 2.3689 | 1.9089 |
| Jan 6, 2025 | 1.9089 | -0.0350 | -1.80% | 1.9439 | 1.9889 | 1.8989 |
| Jan 3, 2025 | 1.9389 | 0.1550 | 8.69% | 1.7839 | 1.9389 | 1.7489 |
| Jan 2, 2025 | 1.7889 | -0.0900 | -4.79% | 1.8789 | 1.9189 | 1.7689 |
| Dec 31, 2024 | 1.8089 | 0.0550 | 3.14% | 1.7539 | 1.8089 | 1.7289 |
| Dec 30, 2024 | 1.7489 | -0.1000 | -5.41% | 1.8489 | 1.8589 | 1.7389 |
| Dec 27, 2024 | 1.8389 | 0.0100 | 0.55% | 1.8289 | 1.9389 | 1.7839 |
| Dec 26, 2024 | 1.8289 | 0.0500 | 2.81% | 1.7789 | 1.8439 | 1.7789 |
| Dec 24, 2024 | 1.8039 | 0.0400 | 2.27% | 1.7639 | 1.8189 | 1.7439 |
| Dec 23, 2024 | 1.7589 | -0.0250 | -1.40% | 1.7839 | 1.8039 | 1.7389 |
| Dec 20, 2024 | 1.7989 | -0.0150 | -0.83% | 1.8139 | 1.8239 | 1.7289 |
| Dec 19, 2024 | 1.8189 | 0.0050 | 0.28% | 1.8139 | 1.8689 | 1.7689 |
| Dec 18, 2024 | 1.7489 | -0.2150 | -10.95% | 1.9639 | 1.9639 | 1.7189 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Inovio Pharmaceuticals Company profile
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system''s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.| Industry: | Biotechnology & Medical Research (NEC) |
6769 Mesa Ridge Rd.
SAN DIEGO
CALIFORNIA 92121
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com